Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: National Health Service, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, University of Pisa, OHSU Knight Cancer Institute, Princess Margaret Cancer Centre, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo, The University of Sydney, Eisai (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2776898950